Kevin Scott Emerick, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 39 | 2023 | 2734 | 4.270 |
Why?
|
| Carcinoma, Squamous Cell | 25 | 2023 | 4034 | 2.710 |
Why?
|
| Skin Neoplasms | 22 | 2023 | 5686 | 2.530 |
Why?
|
| Surgical Flaps | 20 | 2021 | 1640 | 2.360 |
Why?
|
| Sentinel Lymph Node Biopsy | 6 | 2021 | 709 | 1.600 |
Why?
|
| Free Tissue Flaps | 9 | 2023 | 328 | 1.260 |
Why?
|
| Laryngectomy | 7 | 2020 | 248 | 1.120 |
Why?
|
| Carcinoma, Merkel Cell | 6 | 2022 | 300 | 1.080 |
Why?
|
| Otolaryngology | 6 | 2019 | 645 | 0.920 |
Why?
|
| Parotid Gland | 3 | 2023 | 168 | 0.830 |
Why?
|
| Lymphatic Metastasis | 7 | 2021 | 2924 | 0.820 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2018 | 1107 | 0.790 |
Why?
|
| Ranula | 2 | 2018 | 11 | 0.750 |
Why?
|
| Laryngeal Neoplasms | 7 | 2018 | 512 | 0.750 |
Why?
|
| Larynx, Artificial | 5 | 2014 | 69 | 0.710 |
Why?
|
| Neoplasm Staging | 16 | 2023 | 11031 | 0.660 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 2 | 2010 | 180 | 0.660 |
Why?
|
| Facial Nerve Diseases | 2 | 2016 | 50 | 0.620 |
Why?
|
| Parotid Neoplasms | 3 | 2019 | 155 | 0.560 |
Why?
|
| Oropharyngeal Neoplasms | 5 | 2022 | 477 | 0.530 |
Why?
|
| Smiling | 1 | 2016 | 72 | 0.530 |
Why?
|
| Neuralgia | 1 | 2021 | 570 | 0.510 |
Why?
|
| Melanoma | 5 | 2023 | 5510 | 0.500 |
Why?
|
| Ear Auricle | 1 | 2014 | 32 | 0.490 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2022 | 545 | 0.470 |
Why?
|
| Facial Neoplasms | 1 | 2014 | 121 | 0.450 |
Why?
|
| Carcinoma, Mucoepidermoid | 2 | 2019 | 88 | 0.450 |
Why?
|
| Lymphoma, B-Cell | 2 | 2010 | 931 | 0.440 |
Why?
|
| Drainage | 2 | 2016 | 1142 | 0.440 |
Why?
|
| Facial Paralysis | 1 | 2016 | 338 | 0.410 |
Why?
|
| Clavicle | 6 | 2018 | 209 | 0.410 |
Why?
|
| Retrospective Studies | 43 | 2023 | 77449 | 0.400 |
Why?
|
| Skull Base | 1 | 2014 | 306 | 0.390 |
Why?
|
| Scalp | 1 | 2014 | 380 | 0.390 |
Why?
|
| Arteries | 2 | 2015 | 1119 | 0.390 |
Why?
|
| Lymph Nodes | 4 | 2021 | 3474 | 0.390 |
Why?
|
| Neoplasm Invasiveness | 7 | 2021 | 3616 | 0.370 |
Why?
|
| Retropharyngeal Abscess | 1 | 2010 | 21 | 0.360 |
Why?
|
| Education, Medical, Graduate | 3 | 2018 | 2291 | 0.340 |
Why?
|
| Forearm | 3 | 2023 | 409 | 0.330 |
Why?
|
| Oncolytic Viruses | 2 | 2023 | 327 | 0.330 |
Why?
|
| Papillomavirus Infections | 4 | 2022 | 1587 | 0.330 |
Why?
|
| Mouth Neoplasms | 3 | 2021 | 601 | 0.330 |
Why?
|
| Jaw Diseases | 1 | 2008 | 90 | 0.310 |
Why?
|
| Nose Diseases | 1 | 2008 | 79 | 0.310 |
Why?
|
| Humans | 99 | 2023 | 744343 | 0.310 |
Why?
|
| Oral Surgical Procedures | 2 | 2021 | 168 | 0.310 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2022 | 252 | 0.300 |
Why?
|
| Range of Motion, Articular | 1 | 2014 | 1578 | 0.300 |
Why?
|
| Surgical Wound Infection | 5 | 2021 | 1540 | 0.300 |
Why?
|
| Facial Bones | 1 | 2008 | 201 | 0.300 |
Why?
|
| Tissue Transplantation | 1 | 2007 | 130 | 0.290 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 3 | 2016 | 312 | 0.280 |
Why?
|
| Adenoids | 1 | 2006 | 33 | 0.280 |
Why?
|
| Cystadenocarcinoma | 1 | 2005 | 55 | 0.270 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2006 | 90 | 0.270 |
Why?
|
| Indians, North American | 3 | 2014 | 355 | 0.270 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 604 | 0.270 |
Why?
|
| Tonsillar Neoplasms | 1 | 2005 | 51 | 0.260 |
Why?
|
| Electrocoagulation | 1 | 2006 | 158 | 0.260 |
Why?
|
| Neoplasms, Basal Cell | 2 | 2022 | 31 | 0.260 |
Why?
|
| Postoperative Complications | 14 | 2021 | 15295 | 0.260 |
Why?
|
| Male | 55 | 2021 | 350118 | 0.250 |
Why?
|
| Middle Aged | 43 | 2021 | 213383 | 0.250 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2007 | 339 | 0.250 |
Why?
|
| Aged | 36 | 2022 | 163280 | 0.250 |
Why?
|
| Clinical Competence | 3 | 2019 | 4687 | 0.250 |
Why?
|
| Punctures | 5 | 2014 | 374 | 0.250 |
Why?
|
| Adenoidectomy | 1 | 2006 | 159 | 0.250 |
Why?
|
| Physicians, Family | 1 | 2006 | 345 | 0.240 |
Why?
|
| Wound Healing | 4 | 2014 | 2785 | 0.240 |
Why?
|
| Treatment Outcome | 23 | 2020 | 63114 | 0.240 |
Why?
|
| Graft Survival | 6 | 2018 | 3737 | 0.240 |
Why?
|
| Cutaneous Fistula | 3 | 2016 | 78 | 0.240 |
Why?
|
| Skull | 1 | 2008 | 813 | 0.230 |
Why?
|
| Tracheal Stenosis | 1 | 2006 | 226 | 0.230 |
Why?
|
| Bone Transplantation | 1 | 2008 | 907 | 0.230 |
Why?
|
| Anastomosis, Surgical | 1 | 2007 | 987 | 0.220 |
Why?
|
| Venous Thrombosis | 2 | 2016 | 1239 | 0.220 |
Why?
|
| Mandible | 1 | 2007 | 740 | 0.220 |
Why?
|
| Paranasal Sinus Neoplasms | 2 | 2022 | 234 | 0.220 |
Why?
|
| Immunoconjugates | 1 | 2010 | 901 | 0.210 |
Why?
|
| Indocyanine Green | 1 | 2023 | 239 | 0.200 |
Why?
|
| Skin Transplantation | 1 | 2007 | 1074 | 0.200 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2005 | 506 | 0.200 |
Why?
|
| Female | 47 | 2021 | 380194 | 0.200 |
Why?
|
| Antibiotic Prophylaxis | 3 | 2016 | 639 | 0.200 |
Why?
|
| Prognosis | 11 | 2021 | 29063 | 0.200 |
Why?
|
| Prosthesis Implantation | 3 | 2011 | 642 | 0.200 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2006 | 329 | 0.200 |
Why?
|
| Papillomaviridae | 3 | 2022 | 1119 | 0.190 |
Why?
|
| Aged, 80 and over | 13 | 2021 | 57776 | 0.190 |
Why?
|
| Chemoprevention | 1 | 2023 | 319 | 0.190 |
Why?
|
| Trachea | 3 | 2011 | 1076 | 0.180 |
Why?
|
| Melanosis | 1 | 2021 | 78 | 0.180 |
Why?
|
| Blood Transfusion | 2 | 2018 | 1301 | 0.180 |
Why?
|
| Neck Dissection | 3 | 2017 | 197 | 0.180 |
Why?
|
| Speech Disorders | 1 | 2021 | 189 | 0.180 |
Why?
|
| Xeroderma Pigmentosum | 1 | 2019 | 31 | 0.180 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 13695 | 0.180 |
Why?
|
| Immunotherapy | 4 | 2023 | 4445 | 0.170 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 221 | 0.170 |
Why?
|
| Sublingual Gland | 1 | 2018 | 10 | 0.160 |
Why?
|
| Risk Assessment | 9 | 2021 | 23338 | 0.160 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2019 | 369 | 0.160 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2018 | 61 | 0.160 |
Why?
|
| Cohort Studies | 10 | 2021 | 40561 | 0.160 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 4851 | 0.150 |
Why?
|
| Neoplasms, Squamous Cell | 2 | 2021 | 96 | 0.150 |
Why?
|
| Hyperplasia | 1 | 2021 | 1185 | 0.150 |
Why?
|
| Melanocytes | 1 | 2021 | 515 | 0.150 |
Why?
|
| Anophthalmos | 1 | 2017 | 22 | 0.150 |
Why?
|
| Laryngeal Diseases | 1 | 2020 | 241 | 0.150 |
Why?
|
| Jugular Veins | 1 | 2018 | 204 | 0.150 |
Why?
|
| Oncolytic Virotherapy | 1 | 2023 | 498 | 0.150 |
Why?
|
| Tracheotomy | 1 | 2018 | 166 | 0.150 |
Why?
|
| Parotid Diseases | 1 | 2017 | 46 | 0.150 |
Why?
|
| Follow-Up Studies | 9 | 2015 | 39050 | 0.140 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 4149 | 0.140 |
Why?
|
| Internship and Residency | 4 | 2019 | 5788 | 0.140 |
Why?
|
| Models, Biological | 1 | 2013 | 9583 | 0.140 |
Why?
|
| Conjunctival Neoplasms | 1 | 2017 | 79 | 0.140 |
Why?
|
| Esophagus | 3 | 2011 | 1019 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2018 | 20129 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2022 | 1770 | 0.130 |
Why?
|
| Cervicoplasty | 1 | 2015 | 8 | 0.130 |
Why?
|
| Deglutition Disorders | 1 | 2021 | 605 | 0.130 |
Why?
|
| Paranasal Sinuses | 2 | 2021 | 250 | 0.130 |
Why?
|
| Estrogen Receptor alpha | 1 | 2019 | 577 | 0.130 |
Why?
|
| Urinary Tract Infections | 1 | 2021 | 788 | 0.130 |
Why?
|
| Human papillomavirus 16 | 1 | 2017 | 262 | 0.130 |
Why?
|
| Tongue Neoplasms | 1 | 2017 | 180 | 0.130 |
Why?
|
| Actinomycosis | 1 | 2014 | 21 | 0.130 |
Why?
|
| Clostridium Infections | 1 | 2021 | 548 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 1038 | 0.120 |
Why?
|
| Bacteremia | 1 | 2021 | 962 | 0.120 |
Why?
|
| Hospitals, University | 1 | 2016 | 571 | 0.120 |
Why?
|
| Mastoid | 1 | 2014 | 92 | 0.120 |
Why?
|
| Combined Modality Therapy | 6 | 2016 | 8642 | 0.120 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2014 | 117 | 0.120 |
Why?
|
| Pharynx | 1 | 2017 | 413 | 0.120 |
Why?
|
| Head | 1 | 2019 | 880 | 0.120 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2010 | 3712 | 0.120 |
Why?
|
| Area Under Curve | 1 | 2018 | 1654 | 0.120 |
Why?
|
| Frozen Sections | 1 | 2014 | 155 | 0.120 |
Why?
|
| Ear Neoplasms | 1 | 2014 | 117 | 0.120 |
Why?
|
| Postoperative Hemorrhage | 2 | 2015 | 413 | 0.120 |
Why?
|
| Length of Stay | 6 | 2021 | 6309 | 0.120 |
Why?
|
| Conjunctiva | 1 | 2017 | 494 | 0.110 |
Why?
|
| Schwann Cells | 1 | 2014 | 195 | 0.110 |
Why?
|
| Adult | 18 | 2021 | 214055 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2006 | 2987 | 0.110 |
Why?
|
| Salvage Therapy | 2 | 2011 | 1275 | 0.110 |
Why?
|
| Ligands | 1 | 2020 | 3282 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2021 | 35421 | 0.110 |
Why?
|
| Confidence Intervals | 1 | 2018 | 2971 | 0.110 |
Why?
|
| Shoulder | 1 | 2014 | 299 | 0.100 |
Why?
|
| Nerve Tissue | 1 | 2012 | 79 | 0.100 |
Why?
|
| Pilot Projects | 4 | 2021 | 8324 | 0.100 |
Why?
|
| Needs Assessment | 1 | 2018 | 1147 | 0.100 |
Why?
|
| Infratentorial Neoplasms | 1 | 2012 | 94 | 0.100 |
Why?
|
| Bibliometrics | 1 | 2015 | 339 | 0.100 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2012 | 129 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 14722 | 0.100 |
Why?
|
| SEER Program | 2 | 2013 | 1508 | 0.100 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2011 | 50 | 0.100 |
Why?
|
| Pain, Postoperative | 1 | 2021 | 1643 | 0.100 |
Why?
|
| Treatment Refusal | 1 | 2014 | 421 | 0.100 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2014 | 298 | 0.090 |
Why?
|
| Cell Cycle Proteins | 1 | 2022 | 3462 | 0.090 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2012 | 190 | 0.090 |
Why?
|
| ROC Curve | 1 | 2018 | 3527 | 0.090 |
Why?
|
| Oropharynx | 1 | 2011 | 127 | 0.090 |
Why?
|
| Neuroma, Acoustic | 1 | 2014 | 451 | 0.090 |
Why?
|
| Survival Rate | 4 | 2018 | 12788 | 0.090 |
Why?
|
| Human papillomavirus 11 | 1 | 2009 | 14 | 0.090 |
Why?
|
| Diagnosis, Differential | 5 | 2012 | 12959 | 0.090 |
Why?
|
| Pneumonia | 1 | 2021 | 2133 | 0.090 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 2009 | 57 | 0.090 |
Why?
|
| Graft Rejection | 3 | 2018 | 4397 | 0.090 |
Why?
|
| Skin | 1 | 2023 | 4364 | 0.090 |
Why?
|
| Speech, Alaryngeal | 1 | 2009 | 32 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2018 | 2250 | 0.080 |
Why?
|
| Young Adult | 8 | 2021 | 56430 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2021 | 2265 | 0.080 |
Why?
|
| Speech Intelligibility | 1 | 2009 | 81 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 9274 | 0.080 |
Why?
|
| Papilloma | 1 | 2009 | 148 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 19905 | 0.080 |
Why?
|
| Biopsy | 2 | 2010 | 6756 | 0.080 |
Why?
|
| Pharyngeal Diseases | 1 | 2009 | 133 | 0.080 |
Why?
|
| Publishing | 1 | 2015 | 833 | 0.080 |
Why?
|
| Occlusive Dressings | 1 | 2007 | 50 | 0.080 |
Why?
|
| Massachusetts | 5 | 2021 | 8663 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2022 | 5853 | 0.070 |
Why?
|
| Fistula | 1 | 2009 | 220 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 4479 | 0.070 |
Why?
|
| Splints | 1 | 2007 | 111 | 0.070 |
Why?
|
| Risk Factors | 10 | 2020 | 72290 | 0.070 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2006 | 27 | 0.070 |
Why?
|
| Gene Expression | 1 | 2019 | 7799 | 0.070 |
Why?
|
| Apoptosis | 2 | 2020 | 9727 | 0.070 |
Why?
|
| Immunohistochemistry | 3 | 2019 | 11366 | 0.070 |
Why?
|
| Antibodies, Viral | 1 | 2017 | 3176 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 2529 | 0.060 |
Why?
|
| Hematocrit | 2 | 2018 | 636 | 0.060 |
Why?
|
| Osteogenesis, Distraction | 1 | 2007 | 219 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 6538 | 0.060 |
Why?
|
| South Dakota | 2 | 2014 | 30 | 0.060 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 3674 | 0.060 |
Why?
|
| Hypertrophy | 1 | 2006 | 569 | 0.060 |
Why?
|
| Neoplasms | 2 | 2023 | 21683 | 0.060 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2019 | 713 | 0.060 |
Why?
|
| Bacteria | 1 | 2014 | 2114 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2021 | 9239 | 0.060 |
Why?
|
| United States | 7 | 2021 | 69872 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2014 | 10252 | 0.060 |
Why?
|
| Adaptation, Psychological | 1 | 2014 | 2576 | 0.060 |
Why?
|
| Patient Readmission | 1 | 2017 | 3114 | 0.060 |
Why?
|
| Adolescent | 6 | 2019 | 85781 | 0.060 |
Why?
|
| Pharyngectomy | 2 | 2014 | 45 | 0.050 |
Why?
|
| Carcinoma | 1 | 2014 | 2375 | 0.050 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2021 | 687 | 0.050 |
Why?
|
| Fatal Outcome | 2 | 2021 | 1850 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2022 | 12208 | 0.050 |
Why?
|
| Random Allocation | 1 | 2007 | 2429 | 0.050 |
Why?
|
| Microcirculation | 1 | 2007 | 1286 | 0.050 |
Why?
|
| Students, Medical | 1 | 2014 | 1862 | 0.050 |
Why?
|
| Fluorescence | 1 | 2023 | 751 | 0.050 |
Why?
|
| Internet | 1 | 2013 | 3064 | 0.050 |
Why?
|
| Tumor Burden | 2 | 2021 | 1915 | 0.050 |
Why?
|
| Prospective Studies | 4 | 2021 | 53288 | 0.050 |
Why?
|
| Physician-Patient Relations | 1 | 2014 | 3229 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 1677 | 0.050 |
Why?
|
| Interdisciplinary Studies | 1 | 2021 | 89 | 0.050 |
Why?
|
| Disease Progression | 4 | 2021 | 13284 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 3508 | 0.050 |
Why?
|
| Radius | 1 | 2023 | 422 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2010 | 5974 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 3923 | 0.040 |
Why?
|
| Deglutition | 1 | 2021 | 197 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2015 | 3309 | 0.040 |
Why?
|
| Palate, Soft | 1 | 2019 | 96 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 2022 | 373 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 2942 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 8949 | 0.040 |
Why?
|
| Mass Screening | 1 | 2014 | 5255 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 15076 | 0.040 |
Why?
|
| Catheter-Related Infections | 1 | 2021 | 252 | 0.040 |
Why?
|
| Patient Discharge | 2 | 2021 | 3313 | 0.040 |
Why?
|
| Professional Autonomy | 1 | 2019 | 177 | 0.040 |
Why?
|
| Dissection | 1 | 2019 | 295 | 0.040 |
Why?
|
| Tissue Engineering | 1 | 2007 | 1880 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2021 | 673 | 0.040 |
Why?
|
| Nasal Cavity | 1 | 2019 | 313 | 0.040 |
Why?
|
| Ultraviolet Rays | 1 | 2022 | 1060 | 0.040 |
Why?
|
| Oncogenes | 1 | 2022 | 1265 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 7181 | 0.030 |
Why?
|
| Clindamycin | 1 | 2016 | 139 | 0.030 |
Why?
|
| Speech | 1 | 2021 | 540 | 0.030 |
Why?
|
| Reoperation | 1 | 2006 | 4201 | 0.030 |
Why?
|
| Workflow | 1 | 2021 | 847 | 0.030 |
Why?
|
| Nose | 1 | 2019 | 509 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 2 | 2021 | 2728 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 8301 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2023 | 1917 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2022 | 11524 | 0.030 |
Why?
|
| Cadaver | 1 | 2019 | 1337 | 0.030 |
Why?
|
| Neck | 1 | 2019 | 697 | 0.030 |
Why?
|
| Incidence | 4 | 2015 | 20947 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2022 | 2225 | 0.030 |
Why?
|
| Quality of Life | 4 | 2021 | 12804 | 0.030 |
Why?
|
| Drug Approval | 1 | 2021 | 742 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 6234 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2022 | 2012 | 0.030 |
Why?
|
| Comorbidity | 1 | 2009 | 10388 | 0.030 |
Why?
|
| Kinetics | 1 | 2022 | 6473 | 0.030 |
Why?
|
| Recurrence | 1 | 2006 | 8340 | 0.030 |
Why?
|
| Cleft Palate | 1 | 2019 | 560 | 0.030 |
Why?
|
| Infant | 2 | 2006 | 35136 | 0.030 |
Why?
|
| Child | 2 | 2016 | 77709 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 1584 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2018 | 1842 | 0.030 |
Why?
|
| Time Factors | 3 | 2014 | 40075 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2006 | 41006 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 1581 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2022 | 1580 | 0.030 |
Why?
|
| Alaska | 1 | 2012 | 68 | 0.030 |
Why?
|
| Esthetics | 1 | 2014 | 306 | 0.030 |
Why?
|
| Cranial Nerve Diseases | 1 | 2012 | 112 | 0.030 |
Why?
|
| Skull Neoplasms | 1 | 2012 | 173 | 0.030 |
Why?
|
| Brain | 2 | 2021 | 26385 | 0.020 |
Why?
|
| Paralysis | 1 | 2012 | 247 | 0.020 |
Why?
|
| Forecasting | 1 | 2020 | 2951 | 0.020 |
Why?
|
| Chromatin | 1 | 2022 | 2934 | 0.020 |
Why?
|
| Rats | 1 | 2007 | 24260 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2017 | 19229 | 0.020 |
Why?
|
| Focus Groups | 1 | 2014 | 1321 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 6895 | 0.020 |
Why?
|
| Opportunistic Infections | 1 | 2012 | 389 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 7279 | 0.020 |
Why?
|
| Workload | 1 | 2015 | 850 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 3597 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 9959 | 0.020 |
Why?
|
| Proteomics | 1 | 2022 | 3638 | 0.020 |
Why?
|
| Career Choice | 1 | 2014 | 744 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 25043 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 2759 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 2016 | 1400 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2017 | 2183 | 0.020 |
Why?
|
| Educational Status | 1 | 2015 | 2540 | 0.020 |
Why?
|
| Organ Preservation | 1 | 2009 | 331 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2018 | 3743 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2009 | 629 | 0.020 |
Why?
|
| Carboplatin | 1 | 2009 | 801 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2022 | 16689 | 0.020 |
Why?
|
| Cartilage | 1 | 2009 | 818 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 3586 | 0.020 |
Why?
|
| Enteral Nutrition | 1 | 2011 | 763 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 12354 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2015 | 2266 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 2212 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 12245 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2009 | 1619 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2019 | 3749 | 0.010 |
Why?
|
| Prosthesis Failure | 1 | 2009 | 1206 | 0.010 |
Why?
|
| Probability | 1 | 2009 | 2505 | 0.010 |
Why?
|
| Remission Induction | 1 | 2009 | 2386 | 0.010 |
Why?
|
| Logistic Models | 1 | 2018 | 13408 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 2886 | 0.010 |
Why?
|
| Cisplatin | 1 | 2009 | 1662 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2020 | 21746 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 2009 | 2110 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 9438 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2011 | 5078 | 0.010 |
Why?
|
| Health Status Disparities | 1 | 2012 | 1797 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 7785 | 0.010 |
Why?
|
| Contrast Media | 1 | 2012 | 5300 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2014 | 10481 | 0.010 |
Why?
|
| Radiography | 1 | 2009 | 7023 | 0.010 |
Why?
|
| Pain | 1 | 2012 | 4986 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2019 | 23403 | 0.010 |
Why?
|
| Animals | 1 | 2007 | 168757 | 0.010 |
Why?
|